Long COVID: a long road ahead.

Long COVID: a long road ahead.

Publication date: Oct 11, 2025

The SARS-CoV-2 pandemic caused an estimated 400 million people worldwide to experience Long COVID and post-COVID complications leading to significant chronic illness and disability with its devastating physical, societal and economic consequences. Since post-acute infectious syndromes have not been given adequate consideration prior to the pandemic, many millions of people with Long COVID worldwide have been left disabled as currently available therapies are largely symptomatic and only partially effective. A case of a previously healthy woman with Long COVID and post-COVID autonomic dysfunction and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is presented here from the perspective of a physician-patient relationship and a broader context of medical care and public health. Immunologic and autonomic mechanistic factors and therapies as these relate to Long COVID are highlighted. Complexities and issues pertaining to patient care, public health and education of neurologists and other specialists regarding Long COVID, dysautonomia and ME/CFS diagnosis and treatment are discussed, in conjunction with the need to develop and diversify effective therapies for people living with these highly disabling conditions.

Open Access PDF

Concepts Keywords
Covid autonomic dysfunction
Economic brain health
Immunologic dysautonomia
Neurologists Long COVID
Pandemic neurology
public health

Semantics

Type Source Name
disease MESH Long COVID
disease MESH chronic illness
disease MESH syndromes
disease MESH myalgic encephalomyelitis
disease MESH dysautonomia
disease MESH COVID 19
disease MESH infection
disease MESH fatigue
disease MESH dizziness
disease MESH orthostatic intolerance
disease MESH cognitive impairment
disease MESH bed
disease MESH anhedonia
disease MESH psychiatric disorder
drug DRUGBANK Polyethylene glycol
pathway REACTOME Reproduction
disease MESH pain
disease MESH headache
drug DRUGBANK Tropicamide
disease MESH anxiety
disease MESH trauma
disease MESH plan
pathway REACTOME Immune System
drug DRUGBANK Medical air
disease MESH dys
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Silver
disease MESH orthostatic hypotension
disease MESH demyelinating disorders
disease MESH brain disorders
disease MESH dis
disease MESH neurologic disorders
drug DRUGBANK Immune Globulin Human
disease MESH autoimmune diseases
disease MESH Neuroinflammation
pathway REACTOME Metabolism
drug DRUGBANK Cysteamine
drug DRUGBANK Carboxyamidotriazole
disease MESH reinfection
disease MESH cancer
disease MESH cognitive symptoms

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *